← All trials
NCT05357040
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2021
- Primary completion
- Feb 1, 2024
- Completion date
- Apr 1, 2024
- First posted
- May 2, 2022
- Last posted
- Dec 22, 2022
- Enrollment
- 172
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of ChicagoLead sponsor
- Monash UniversityCollaborator
- University of ChicagoOverall official - principal investigator
- The Alfred HospitalOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.